PRESS RELEASE | Euformatics and Kemomed in distribution partnership for world-leading NGS bioinformatics software in Slovenia and Croatia
LJUBLJANA, Slovenia, July 2021.
Finnish bioinformatics software company Euformatics, which develops and sells world-leading NGS interpretation and quality control tools, has expanded its European customer reach through a distributor agreement with Kemomed d.o.o., covering the Slovenian and Croatian markets.
The latest in the Espoo, Finland based company’s distributor agreement portfolio, the announcement of the deal with Kemomed is for the whole omnomics Suite group of software products: NGS test validation, sample quality control and variant interpretation in a clinical environment. The agreement builds a stronger base for Euformatics’ representation on the ground in central Europe, following the partnership signed with Dynex in the Czech Republic and Slovakia in 2020 and Analityk Genetyka in Poland last month. As the official Illumina distributor for Slovenia and Croatia, Kemomed is well-placed to be able to offer Euformatics’ software to its growing installed base of Illumina users.
Although relatively small markets, uptake of NGS technologies is growing strongly in Slovenia and Croatia, positioning Kemomed as the ideal partner to offer an end-to-end solution for laboratories running NGS sequencing through their partnership with Illumina. In cases where laboratories are just starting to use NGS techniques, the Euformatics portfolio combined with the current offering from Kemomed is a strong combination; indeed, the agreement gives laboratories in the covered territories access to all the tools they need to perform NGS tests for patient samples.
“As the installed base of NGS instruments is growing fast there is an increasing need for end-to-end solutions for the clinical market in Slovenia and Croatia. The pandemic has resulted in a significant capacity increase in NGS due to virus variant surveillance. Now that vaccinations are starting have an impact and the number of positive cases is going down, we see an opportunity for using the sequencers for patient diagnostics. By being able to offer a full sample QC tool combined with the power of the variant interpretation and annotation capabilities of omnomicsNGS, we believe that laboratories here no longer need to look anywhere else to get a full set-up for their NGS activities”, says Andrej Vuga, Kemomed CEO.
Euformatics CEO, Tommi Kaasalainen, comments “We have understood that having a solid grounding in our back yard is really important. While we already have customers throughout Europe, we are determined to make sure that all NGS laboratories get access to world-class interpretation and QC tools. As we have been working with the Kemomed team over the first half of the year we have already seen their impressive expertise in the field of NGS. We look forward to engaging thought leaders in Slovenia and Croatia together with Kemomed to build a strong foundation for growing the clinical NGS market in these countries”.
The agreement was announced on the same day as another distribution contract signed between the Finnish company and PT Pandu Biosains in Indonesia, highlighting Euformatics drive to expand and grow its network of partners in 2021.
Kemomed is a dealership and service providing company, established in 1996 in Slovenia. Further growth and development lead the company to partner with many leading companies from the fields of genetics, biotechnology, molecular biology, analytical chemistry instruments, and consumables. In 2005 we established and accredited an advanced laboratory for pipette calibration, and we built up our own service department to offer after-sales support for installed instruments. As a part of KEFO Group, we are seeing our company as a leader in personalized medicine solutions, NGS, 3D bioprinting, advanced analytical chemistry solutions, and service providing.
Euformatics is a Finnish software company that specialises in high standard bioinformatics tools for genomic data interpretation. Since 2010, Euformatics has been helping medical doctors and molecular genetics laboratories provide better precision medicine for cancer, common or rare disease diagnostics. At present, our core solution is the omnomics Suite which includes omnomicsNGS; for clinical analysis and reporting of patient NGS data, and omnomicsQ; for NGS data quality management.
For more information, please visit our website www.euformatics.com